tetano
Editor, Senior Moderator
Antiviral Res. 2016 Feb 9. pii: S0166-3542(16)30015-8. doi: 10.1016/j.antiviral.2016.01.012. [Epub ahead of print]
[h=1]Meeting report: 4th ISIRVAntiviral Group Conference: Novel Antiviral Therapies for Influenza and Other Respiratory Viruses.[/h] McKimm-Breschkin JL[SUP]1[/SUP], Fry A[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4[SUP]th[/SUP] Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of several virus targets and key host cell factors involved in virus replication or mediating the inflammatory response. Virus targets included the influenza haemagglutinin, neuraminidase and M2 proteins, and both the respiratory syncytial virus and influenza polymerases and nucleoproteins. Therapies for rhinoviruses and MERS and SARS coronaviruses were also discussed. With the emerging development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. Topics covered all aspects from structural and molecular biology to preclinical and clinical studies. The importance of suitable clinical trial endpoints and regulatory issues were also discussed from the perspectives of both industry and government. This meeting summary provides an overview, not only for the conference participants, but also for those interested in the current status of antivirals for respiratory viruses.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Antiviral; Influenza; Respiratory virus; isirv-AVG
PMID: 26872862 [PubMed - as supplied by publisher]
[h=1]Meeting report: 4th ISIRVAntiviral Group Conference: Novel Antiviral Therapies for Influenza and Other Respiratory Viruses.[/h] McKimm-Breschkin JL[SUP]1[/SUP], Fry A[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4[SUP]th[/SUP] Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of several virus targets and key host cell factors involved in virus replication or mediating the inflammatory response. Virus targets included the influenza haemagglutinin, neuraminidase and M2 proteins, and both the respiratory syncytial virus and influenza polymerases and nucleoproteins. Therapies for rhinoviruses and MERS and SARS coronaviruses were also discussed. With the emerging development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. Topics covered all aspects from structural and molecular biology to preclinical and clinical studies. The importance of suitable clinical trial endpoints and regulatory issues were also discussed from the perspectives of both industry and government. This meeting summary provides an overview, not only for the conference participants, but also for those interested in the current status of antivirals for respiratory viruses.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Antiviral; Influenza; Respiratory virus; isirv-AVG
PMID: 26872862 [PubMed - as supplied by publisher]